Association between Microalbuminuria and MYH9 Gene Polymorphisms in Hypertensive Iraqi Patients with Metabolic Syndrome

  • Alaa Fahem Jasim Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq.
  • Fadhil Jawad Al-Tu’ma Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Kerbala, Iraq.
  • Dhafir Abdul-Mahdi Faisal College of Pharmacy, University of Kufa, Najaf, Iraq.

Abstract

Objective: The presented work aimed to study the correlation between micro-albuminuria and MYH9 (T˃C) (rs3752462) gene polymorphisms in metabolic syndrome of Iraqi patients.
Methods: This study was a cross - sectional study. Sample size was 140 persons of both gender selected randomly between 1st , April. , 2019 to 15th, Aug. , 2020. They are divided into two groups, 80 with metabolic syndrome patients and 60 with control groups subdivided into another two groups: 30 persons with obese and 30 persons without obese. The distribution of sample according to the gender, the number of males had metabolic syndrome were (47) and female (33), but in obese healthy control the number of males were (19) and female (11), while in non-obese healthy control the number of males were (15) and female (15). The age groups were ranged between (40-60) years. Typing of MYH9 was performed by refractory mutation system-polymerase chain reaction (ARMS-PCR). The current study was performed to investigate the SNPs that affected MYH9 gene which was (T˃C) (rs3752462).
Results: There was a significant difference between blood sugar, HbA1c, total cholesterol, TG, VLDL-C, LDL-C, blood urea, micro-albuminuria, BMI and HOMA-IR in metabolic syndrome patients as compared with healthy control groups (P ≤ 0.01). The significant result (P ≤ 0.01) were appeared between (TT) for MYH9 genotype patients and obese control with biochemical parameters (Blood glucose, HbA1c, TC, TG, VLDL-C and LDL-C). The correlation between (TT) SNP for MYH9 genotype patients and non - obese control with biochemical parameters is significant result (P ≤ 0.01 and P ≤ 0.05)  (Blood glucose, HbA1c, insulin, TC, TG, VLDL-C, LDL-C, urea and micro-albuminuria). The significant result (P ≤ 0.01 and P ≤ 0.05) were appeared between (CT) for MYH9 genotype patients and obese control with biochemical parameters (Blood glucose, HbA1c, TC, TG and VLDL-C) respectively.
Conclusion: There is a significant difference between blood glucose, HbA1c, total cholesterol, TG, VLDL-C, LDL-C, blood urea, micro-albuminuria, BMI and HOMA-IR in metabolic syndrome patients and healthy control groups (P ≤ 0.01). Also a significant result (P ≤ 0.01) obtained between (TT) for MYH9 genotype patients and obese and non-obese control with some biochemical parameters. (P ≤ 0.01 and P ≤ 0.05). The significant result (P ≤ 0.01 and P ≤ 0.05) appear between (CT) for MYH9 genotype patients and obese control with some biochemical parameters.
share this Article by

References

1. GRUNDY, Scott M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology, 2006, 47.6: 1093-1100.‏

2. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? June 2006;Volume 83(Issue 6).
3. GRUNDY, Scott M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature reviews Drug discovery, 2006, 5.4: 295-309.‏
4. MOLLER, David E.; KAUFMAN, Keith D. Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med., 2005, 56: 45-62.‏
5. ECKEL, Robert H., et al. The metabolic syndrome. The lancet, 2010, 375.9710: 181-183.‏
6. LAKKA, Hanna-Maaria, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama, 2002, 288.21: 2709-2716.‏
7. HUNT, KELLY, et al. NCEP versus WHO metabolic syndrome in relation to all cause and cardiovascular mortality in the San Antonio Heart Study (SAHS). Diabetes, 2003, 52.‏
8. HANSEN, Matthew L.; GUNN, Paul W.; KAELBER, David C. Underdiagnosis of hypertension in children and adolescents. Jama, 2007, 298.8: 874-879.‏.
9. AMERICAN DIABETES ASSOCIATION, et al. Standards of medical care in diabetes—2010. Diabetes care, 2010, 33.Supplement 1: S11-S61.
‏10. BAYNES, Habtamu W. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J diabetes metab, 2015, 6.5: 1-9.‏
11. CHOBANIAN, Aram V. National heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee: the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama, 2003, 289: 2560-2572.‏.
12. ARRONDEL, Christelle, et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. Journal of the American Society of Nephrology, 2002, 13.1: 65-74.‏
13. Marini M BM, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M, Marini M, Bruschi M, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M,Marini M, Bruschi M, Pecci A, Romagnoli R, Musante L, Cand. Non-muscle myosin heavy chain iia and iib interact and co-localize in living cells: Relevance for myh9-related disease. 2016, Vol.41, No. 6.
14. CHENG, Wenrong, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. Nephrology Dialysis Transplantation, 2011, 26.8: 2544-2549.‏
15. BEHAR, Doron M., et al. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Human molecular genetics, 2010, 19.9: 1816-1827.‏.
16. PATTARO, Cristian, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney international, 2009, 76.3: 297-306.‏
17. KOPP, Jeffrey B., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature genetics, 2008, 40.10: 1175-1184.‏
18. LIU, Liping, et al. Association of MYH9 polymorphisms with hypertension in patients with chronic kidney disease in China. Kidney and Blood Pressure Research, 2016, 41.6: 956-965.‏
19. FREEDMAN, Barry I., et al. The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. American journal of nephrology, 2010, 32.1: 66-72.‏
20. LIPKOWITZ, M. S., et al. Association analysis of the non-muscle myosin heavy chain 9 gene (MYH9) in hypertensive nephropathy: African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol, 2009, 20: 56A.‏
21. PALANIAPPAN, Latha; CARNETHON, Mercedes; FORTMANN, Stephen P. Association between microalbuminuria and the metabolic syndrome: NHANES III. American journal of hypertension, 2003, 16.11: 952-958.‏
22. KAUR, Jaspinder. Assessment and screening of the risk factors in metabolic syndrome. Medical sciences, 2014, 2.3: 140-152.‏.
23. KATZMARZYK, Peter T., et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Medicine and science in sports and exercise, 2003, 35.10: 1703-1709.‏
24. BAHREINIAN, MARYAM, and Ahmad Esmaillzadeh. "Opinion: quantity and quality of carbohydrate intake in Iran: a target for nutritional intervention." (2012): 648-649.‏
25. Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. International journal of preventive medicine. 2014;5(4):373.
26. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Medicine & Science in Sports & Exercise. 2007;39(8):1435-45.
27. Koochek A, Johansson S, Kocturk T, Sundquist J, Sundquist K. Physical activity and body mass index in elderly Iranians in Sweden: a population-based study. European journal of clinical nutrition. 2008;62(11):1326-32.
28. Simoes EJ, Kobau R, Kapp J, Waterman B, Mokdad A, Anderson L. Associations of physical activity and body mass index with activities of daily living in older adults. Journal of community health. 2006;31(6):453-67.
29. Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. Journal of clinical lipidology. 2014;8(2):206-16.
30. Karpov Y, Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovascular diabetology. 2015;14(1):115.
31. Abujbara M, Batieha A, Khader Y, Jaddou H, El-Khateeb M, Ajlouni K. The Prevalence of dyslipidemia among Jordanians. Journal of lipids. 2018;2018.
32. Penesova A, Cizmarova E, Belan V, Blazicek P, Imrich R, Vlcek M, et al. Insulin resistance in young, lean male subjects with essential hypertension. Journal of human hypertension. 2011;25(6):391-400.
33. Sinha S, Qazi SA, Banik S, Islam MZ. Correlation study of insulin resistance and essential hypertension among Bangladeshi male volunteers. Journal of Young Pharmacists. 2015;7(3):200.
34. Sarafidis P, Lasaridis A, Nilsson P, Pikilidou M, Stafilas P, Kanaki A, et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. Journal of human hypertension. 2007;21(9):709-16.
35. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Archives of Internal Medicine. 2001;161(6):886-91.
36. Kumar A, Rekha N, Raghav ED. A Study of Microalbuminuria in Patients with Essential Hypertension. International Journal of Contemporary Medical Research. 2016.
37. Liu L, Wang C, Mi Y, Liu D, Li L, Fan J, et al. Association of myh9 polymorphisms with hypertension in patients with chronic kidney disease in china. Kidney and Blood Pressure Research. 2016;41(6):956-65.
38. Masconi K. The occurance of genetic variations in the MYH9 gene and their association with CKD in a mixed South African population: Stellenbosch: Stellenbosch University; 2012.
39. Bondzie PA. New insights into the molecular regulation of kidney disease: contributions of APOL1 and MYH9: Boston University; 2014.
40. Zhao H, Ma L, Yan M, Wang Y, Zhao T, Zhang H, et al. Association between MYH9 and APOL1 gene polymorphisms and the risk of diabetic kidney disease in patients with Type 2 diabetes in a Chinese Han population. Journal of diabetes research. 2018;2018.
41. Ling C, Cai C, Chang B, Shi W, Wei F, Yu P, et al. MYH9 gene polymorphisms may be associated with cerebrovascular blood flow in patients with type 2 diabetes. Genet Mol Res. 2015;14(1):1008-16.
42. Franceschini N, Voruganti VS, Haack K, Almasy L, Laston S, Göring HH, et al. The association of the MYH9 gene and kidney outcomes in American Indians: the Strong Heart Family Study. Human genetics. 2010;127(3):295-301.
Published
2021-04-26
How to Cite
JASIM, Alaa Fahem; AL-TU’MA, Fadhil Jawad; FAISAL, Dhafir Abdul-Mahdi. Association between Microalbuminuria and MYH9 Gene Polymorphisms in Hypertensive Iraqi Patients with Metabolic Syndrome. Journal of Contemporary Medical Sciences, [S.l.], v. 7, n. 2, p. 122-127, apr. 2021. ISSN 2413-0516. Available at: <http://www.jocms.org/index.php/jcms/article/view/963>. Date accessed: 21 jan. 2022. doi: https://doi.org/10.22317/jcms.v7i2.963.